Publication

Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery

SHINE Study Grp, Voskuil, F. J., Steinkamp, P. J., Zhao, T., van der Vegt, B., Koller, M., Doff, J. J., Jayalakshmi, Y., Hartung, J. P., Gao, J., Sumer, B. D., Witjes, M. J. H. & van Dam, G. M., 1-Dec-2020, In : Nature Communications. 11, 1, p. 3257 10 p., 3257.

Research output: Contribution to journalArticleAcademicpeer-review

APA

SHINE Study Grp, Voskuil, F. J., Steinkamp, P. J., Zhao, T., van der Vegt, B., Koller, M., Doff, J. J., Jayalakshmi, Y., Hartung, J. P., Gao, J., Sumer, B. D., Witjes, M. J. H., & van Dam, G. M. (2020). Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery. Nature Communications, 11(1), 3257. [3257]. https://doi.org/10.1038/s41467-020-16814-4

Author

SHINE Study Grp ; Voskuil, F. J. ; Steinkamp, P. J. ; Zhao, T. ; van der Vegt, B. ; Koller, M. ; Doff, J. J. ; Jayalakshmi, Y. ; Hartung, J. P. ; Gao, J. ; Sumer, B. D. ; Witjes, M. J. H. ; van Dam, G. M. / Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery. In: Nature Communications. 2020 ; Vol. 11, No. 1. pp. 3257.

Harvard

SHINE Study Grp, Voskuil, FJ, Steinkamp, PJ, Zhao, T, van der Vegt, B, Koller, M, Doff, JJ, Jayalakshmi, Y, Hartung, JP, Gao, J, Sumer, BD, Witjes, MJH & van Dam, GM 2020, 'Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery', Nature Communications, vol. 11, no. 1, 3257, pp. 3257. https://doi.org/10.1038/s41467-020-16814-4

Standard

Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery. / SHINE Study Grp; Voskuil, F. J.; Steinkamp, P. J.; Zhao, T.; van der Vegt, B.; Koller, M.; Doff, J. J.; Jayalakshmi, Y.; Hartung, J. P.; Gao, J.; Sumer, B. D.; Witjes, M. J. H.; van Dam, G. M.

In: Nature Communications, Vol. 11, No. 1, 3257, 01.12.2020, p. 3257.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

SHINE Study Grp, Voskuil FJ, Steinkamp PJ, Zhao T, van der Vegt B, Koller M et al. Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery. Nature Communications. 2020 Dec 1;11(1):3257. 3257. https://doi.org/10.1038/s41467-020-16814-4


BibTeX

@article{00fb0cc26f414904875e3d4455b2ac6b,
title = "Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery",
abstract = "Cancer cell metabolism leads to a uniquely acidic microenvironment in solid tumors, but exploiting the labile extracellular pH differences between cancer and normal tissues for clinical use has been challenging. Here we describe the clinical translation of ONM-100, a nanoparticle-based fluorescent imaging agent. This is comprised of an ultra-pH sensitive amphiphilic polymer, conjugated with indocyanine green, which rapidly and irreversibly dissociates to fluoresce in the acidic extracellular tumor microenvironment due to the mechanism of nanoscale macromolecular cooperativity. Primary outcomes were safety, pharmacokinetics and imaging feasilibity of ONM-100. Secondary outcomes were to determine a range of safe doses of ONM-100 for intra-operative imaging using commonly used fluorescence camera systems. In this study (Netherlands National Trial Register #7085), we report that ONM-100 was well tolerated, and four solid tumor types could be visualized both in- and ex vivo in thirty subjects. ONM-100 enables detection of tumor-positive resection margins in 9/9 subjects and four additional otherwise missed occult lesions. Consequently, this pH-activatable optical imaging agent may be clinically beneficial in differentiating previously unexploitable narrow physiologic differences.",
keywords = "CLINICAL-APPLICATIONS, HEAD",
author = "{SHINE Study Grp} and Voskuil, {F. J.} and Steinkamp, {P. J.} and T. Zhao and {van der Vegt}, B. and M. Koller and Doff, {J. J.} and Y. Jayalakshmi and Hartung, {J. P.} and J. Gao and Sumer, {B. D.} and Witjes, {M. J. H.} and {van Dam}, {G. M.} and G{\"u}rsah Kats-Ugurlu",
year = "2020",
month = dec,
day = "1",
doi = "10.1038/s41467-020-16814-4",
language = "English",
volume = "11",
pages = "3257",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery

AU - SHINE Study Grp

AU - Voskuil, F. J.

AU - Steinkamp, P. J.

AU - Zhao, T.

AU - van der Vegt, B.

AU - Koller, M.

AU - Doff, J. J.

AU - Jayalakshmi, Y.

AU - Hartung, J. P.

AU - Gao, J.

AU - Sumer, B. D.

AU - Witjes, M. J. H.

AU - van Dam, G. M.

AU - Kats-Ugurlu, Gürsah

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Cancer cell metabolism leads to a uniquely acidic microenvironment in solid tumors, but exploiting the labile extracellular pH differences between cancer and normal tissues for clinical use has been challenging. Here we describe the clinical translation of ONM-100, a nanoparticle-based fluorescent imaging agent. This is comprised of an ultra-pH sensitive amphiphilic polymer, conjugated with indocyanine green, which rapidly and irreversibly dissociates to fluoresce in the acidic extracellular tumor microenvironment due to the mechanism of nanoscale macromolecular cooperativity. Primary outcomes were safety, pharmacokinetics and imaging feasilibity of ONM-100. Secondary outcomes were to determine a range of safe doses of ONM-100 for intra-operative imaging using commonly used fluorescence camera systems. In this study (Netherlands National Trial Register #7085), we report that ONM-100 was well tolerated, and four solid tumor types could be visualized both in- and ex vivo in thirty subjects. ONM-100 enables detection of tumor-positive resection margins in 9/9 subjects and four additional otherwise missed occult lesions. Consequently, this pH-activatable optical imaging agent may be clinically beneficial in differentiating previously unexploitable narrow physiologic differences.

AB - Cancer cell metabolism leads to a uniquely acidic microenvironment in solid tumors, but exploiting the labile extracellular pH differences between cancer and normal tissues for clinical use has been challenging. Here we describe the clinical translation of ONM-100, a nanoparticle-based fluorescent imaging agent. This is comprised of an ultra-pH sensitive amphiphilic polymer, conjugated with indocyanine green, which rapidly and irreversibly dissociates to fluoresce in the acidic extracellular tumor microenvironment due to the mechanism of nanoscale macromolecular cooperativity. Primary outcomes were safety, pharmacokinetics and imaging feasilibity of ONM-100. Secondary outcomes were to determine a range of safe doses of ONM-100 for intra-operative imaging using commonly used fluorescence camera systems. In this study (Netherlands National Trial Register #7085), we report that ONM-100 was well tolerated, and four solid tumor types could be visualized both in- and ex vivo in thirty subjects. ONM-100 enables detection of tumor-positive resection margins in 9/9 subjects and four additional otherwise missed occult lesions. Consequently, this pH-activatable optical imaging agent may be clinically beneficial in differentiating previously unexploitable narrow physiologic differences.

KW - CLINICAL-APPLICATIONS

KW - HEAD

U2 - 10.1038/s41467-020-16814-4

DO - 10.1038/s41467-020-16814-4

M3 - Article

C2 - 32591522

VL - 11

SP - 3257

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 3257

ER -

ID: 129092034